Key Takeaways
- Margin reset on wage hikes, not demand shock: EBIT margin fell 120 bps QoQ to 13.7%, driven almost entirely by the July 1 pay cycle, while revenue growth, utilization gains, and lower visa costs provided partial offsets.
- Deal wins surged after a Q1 lull: A $75–100 mn TCV Payer deal and multiple PE carveout wins landed in Q2 after some Q1 deals slipped, pushing TCV higher and improving the TCV-to-ACV ratio.
- Hi-tech and Healthcare are the growth engines: Hi-tech is powered by engineering strength and PE carveouts; Healthcare is gaining as a "disruptor" in the Payer segment, winning against tier-1 competitors.
- Management killed forward guidance: The company will no longer give quarterly growth or margin guidance, calling it a "trap," and asks investors to model from TCV, ACV, and headcount disclosures instead.
- What to watch next quarter: Whether the strong Q2 deal book converts to revenue despite management's warning of protracted customer ramp-ups, and whether Q3 furloughs stay within normal seasonality now that the top-client relationship has been restructured.
Margins & Profitability
- Wage hikes took the quarter: The July 1 pay cycle cost 2.7% on EBITDA margin; improved utilization (80.6% vs 78.3%), currency benefit, and absence of visa costs partially offset the hit. One-off marketing event costs and exited-employee expenses were neutralized by a credit from reduced earnout liability on a past acquisition.
- EBIT margin walk: EBIT margin landed at 13.7% vs 14.9% QoQ; H1 EBIT margin was 14.3%, roughly flat YoY, but absolute EBIT grew 19.4% YoY. PAT margin was 10.9% for the quarter; excluding the Q1 one-time $1 bn celebration expense, H1 PAT margin was 11.2% vs 11% in H1 last year.
- Cash conversion strong: OCF to EBITDA was 119% for the quarter; H1 OCF to EBITDA stood at 0.55, marginally ahead of 0.54 in H1 last year, with a full-year target of 0.7.
- Profitability levers are deliberately unpulled: Management called the company "very inefficient," citing utilization at 80.6% against an aspirational 83–84%, SG&A leverage as revenue scales, and costs defrayed over a larger base. The choice was to invest in sales and marketing rather than cut costs to protect growth.
- Medium-term margin ambition intact: The company remains committed to expanding EBITDA margins by 2–3% over the next two to three years, with EBIT margin improvement of 150–200 bps over the same horizon.
Kalra: "We could have, it doesn't take too much to cut costs, it takes a lot to provide growth."
Demand Environment & Deal Wins
- Q1 deals slipped, Q2 landed strong: Deal wins in Q1 were "a tad bit lower" as some deals shifted to Q2; those delayed deals closed in Q2 alongside a healthy organic pipeline, producing a larger TCV and a significantly improved TCV-to-ACV ratio.
- Deal composition is shifting toward larger, longer engagements: Wins included a $75–100 mn TCV Payer deal, multiple PE carveout deals setting up greenfield IT with five-year managed services, and platform engineering wins in financial services. Persistent is winning these against tier-1 competitors, sometimes in Gartner-led processes.
- Conversion is getting more protracted: Customer ramp-ups are taking longer than in prior years, creating more leakage between deal signing and revenue. Management characterized it as a timing issue, not a reduction in total value.
- Sales intensity had to rise to hold the pipeline: To close $100 in bookings, Persistent needed $200+ in pipeline versus a normal $150. The company chose to invest in sales and marketing rather than accept degrowth.
- Top-client relationship restructured: After a "small hiccup," the top client is back on track. Persistent has moved away from revenue-sharing engagements with that client, so the historical Q3 seasonality tied to that relationship may not recur.
Kalra: "If you look at our deal wins for the Q1, that was a tad bit lower than the earlier quarters and we very clearly said some of the deal wins had moved or shifted over to the next quarter. And they have come in along with a very healthy Q2 as well."
Vertical & Geographic Performance
| Vertical / Geography | Trend | Commentary |
|---|---|---|
| Hi-tech | ▲ Strength | Driven by engineering core, PE carveout deals, and GenAI tooling; management says Persistent is "much ahead of competition" and expects it to remain a growth engine. |
| Healthcare | ▲ Gaining | Most traction in the Payer segment (large insurers), with good conversion in Scientific Instruments and Medical Devices. Winning as a "disruptor" against tier-1 Indian and US competitors. |
| BFSI | ▬ Flat | Flat QoQ on a base of strong prior quarters; no further caution from large clients beyond what was already known. Persistent is being brought into renewals and rebids where clients are "fatigued with tier-1 providers." |
| North America | ▬ In line | Grew in line with company average. |
| Europe | ▬ Nearly flat | Nearly flat for the quarter. |
| Rest of World | ▲ Surge | Grew 41.8% QoQ, albeit on a low base. |
- Client concentration improving at the top: Top-50 customers delivered 3.7% QoQ growth, outpacing overall company revenue growth. Customer count grew in all buckets except the $20–30 mn band, where normal project ramp-ups and ramp-downs played out.
People & Talent
- Headcount declined, utilization rose: Gross hiring was slightly lower than total exits, producing a net headcount decline and lifting blended utilization to 80.6% from 78.3%. Bottom performers were managed in line with stated policy.
- Attrition continued to moderate: Attrition fell to 13.5% from 15.5% in Q1, reflecting sector-wide hiring moderation and positive outcomes from the employee value proposition.
- Hiring stance is selective: The company will focus on deploying existing bench while hiring for critical skills laterally based on project requirements over the next several quarters.
- Senior leadership strengthened: Rajiv Sodhi joined as SVP for Hyper Scaler Business and Strategic Alliances (from Microsoft, 16+ years); Ayon Banerjee joined as Chief Strategy and Growth Officer (from ANSR, previously MD & Partner at BCG) to drive strategy toward the $2 bn goal.
- Office footprint expanding: A 250-seater office opened in Kolkata; new offices in Chennai and Cochin are in process; facilities in Noida and Hyderabad are being expanded. The company is encouraging employees to work from office at least two to three days a week.
AI & GenAI
- Early-stage, IP-led experimentation: GenAI engagements are small as both Persistent and customers experiment. The company is building reusable IP for migrations (Teradata to Snowflake, Tableau to Power BI) using GenAI, which it plans to monetize at scale.
- Customer stories are emerging: A sports technology company used AWS Bedrock and LangChain to analyze 35 crore baseball and golf swings for personalized insights; a Fortune 200 molecular diagnostics firm used Google Vertex AI to cut clinical study protocol creation time by up to 90%; a top-tier biotech used Persistent's WingMate accelerator with Azure OpenAI to migrate applications 30% faster.
- Internal adoption underway: PiBOT, a digital assistant powered by Azure Cognitive Services and OpenAI, handles policies, processes, timesheets, and learning paths. SMART QMS, an internal quality management platform powered by GenAI, is used by over 5,000 employees to reuse 1,500+ assets.
- Hyperscaler pull-through expected: GenAI forays by hyperscalers are expected to drive pull-through demand in data readiness and cloud over "the next several quarters and years."
Kalra: "If we can disrupt ourselves, the market for us is huge. So, we are not worried about disrupting ourselves, we are worried about providing the right value to our customers and bringing them the latest and greatest."
Competitive Positioning
- The "disruptor" thesis: Persistent is winning deals by replacing larger competitors in renewals and rebids, particularly in BFSI and Healthcare, where management says clients are "fatigued with tier-1 providers." At $1 bn in revenue, the company argues it has critical mass to scale while still providing management attention and technology solutions that larger peers cannot match.
- Hi-tech differentiation is engineering-led: Persistent's growth in Hi-tech is anchored in product engineering strength, which management calls the "heart of that engine," combined with carveout capabilities for PE firms and GenAI tooling.
- BFSI right-to-win is relationship-driven, not cost-driven: When pressed on differentiation versus larger players with better cost optimization offerings, management cited fatigue with bigger peers and deal wins as evidence, without providing a specific cost-optimization strategy.
Kalra: "I'm proud to say that a small team Persistent, a billion-dollar company, is winning against $10 billion, $20 billion, $30 billion companies, and that's where we are gaining market share in newer customers and even in some of our existing customers."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBIT margin improvement | Expand by 150–200 bps | Over the next 2–3 years |
| EBITDA margin expansion | Expand by 2–3% | Over the next 2–3 years |
| OCF to EBITDA | Achieve 0.7 for the full year | FY24 |
| Utilization | Aspirational target of 83–84% | No date (current: 80.6%) |
| M&A | Active on the M&A front; will report progress | Over the next several quarters |
| Dividend policy | Unchanged for now; will revisit if no further acquisitions over time | Conditional on M&A activity |
| Forward guidance | Will no longer provide quarterly growth or margin guidance | Effective immediately |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue (USD) | $291.71 million, +3.1% QoQ and +14.1% YoY |
| Revenue (INR) | ₹2,411.67 crore, +3.9% QoQ and +17.7% YoY |
| EBIT margin | 13.7%, declined 120 bps QoQ; wage hike impact of 2.7% partially offset by utilization, currency, and lower visa costs |
| EBITDA margin | 16.8%, vs 18.2% in Q1; one-off expenses offset by one-off credit from earnout liability reduction |
| Profit after tax | ₹263.27 crore, 10.9% of revenue; EPS of ₹35 vs ₹30.5 in Q1 |
| H1 revenue (USD) | $574.61 million, +15.6% YoY |
| H1 revenue (INR) | ₹4,732.85 crore, +20.5% YoY |
| H1 EBIT margin | 14.3%, vs 14.5% in H1 FY23; absolute EBIT grew 19.4% YoY |
| Total contract value (TCV) | $479.3 million, with new order book TCV of $313.1 million |
| Annual contract value (ACV) | $315.9 million (component of TCV), with new ACV of $184.2 million |
| Healthcare & Life Sciences growth | 7% QoQ |
| Hi-Tech & Emerging Verticals growth | 3.8% QoQ |
| BFSI growth | Flat QoQ |
| North America revenue growth | 3.1% QoQ in USD terms |
| Europe revenue growth | 0.3% QoQ |
| India revenue growth | 1.3% QoQ |
| Rest of World revenue growth | 41.8% QoQ on a low revenue base |
| Total headcount | 22,842, decline of 282 FTEs from Q1 |
| Blended utilization | 80.6%, up from 78.3% in Q1 |
| Trailing 12-month attrition | 13.5%, down from 15.5% in Q1 |
| Customers in >$1 million bucket | 175, increase of 8 over Q1 |
| Top 5 customer revenue growth | 4.5% QoQ |
| Top 10 customer revenue growth | 2.8% QoQ |
| Top 50 customer revenue growth | 3.7% QoQ, better than overall company growth |
| DSO | 66 days, improved from 67 days in Q1 |
| Cash and investments | ₹1,568.3 crore as of September 30, vs ₹1,409.3 crore at end of June |
| Cash conversion (OCF to EBITDA) | 119% for Q2; H1 at 0.55 vs 0.54 in H1 FY23 |
| Forward contracts outstanding | $240 million at an average rate of 83.92 per dollar |
| ROCE | 30.2%, vs 30.4% in Q1 |
| Effective tax rate | 26%, vs 25.5% in Q1 |
| Freshers onboarded | 277 in Q2 |
| EBIT margin improvement target | 150 to 200 bps over the next two to three years |
| Aspirational utilization range | 83–84%; every 1% utilization improvement impacts PAT by 30 bps |
| ACV revenue conversion leakage | 10–15% currently, vs less than 10% earlier; in rare cases a little more |